Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for ...

In late 2014, when the peak of the Ebola outbreak in western Africa was at its worst, Merck licensed V920 from NewLink Genetics, with the goal of … Full Article http://j.gs/5sTq

Click here to read full article